Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy
Recurrence of breast cancer after mastectomy for DCIS is rare; however, it carries a high mortality rate for those who relapse. Adjuvant tamoxifen after mastectomy demonstrated a significant reduction in the risk of recurrence in ER-positive DCIS. This study supports the decision to prescribe adjuvant ET in patients with DCIS who underwent mastectomy.
Authors
- Norasate Samarnthai (ORCID: https://orcid.org/0000-0001-8830-5404)
- Warapan Numprasit (ORCID: https://orcid.org/0000-0001-9027-7406)
- Netchanok Sae-sim
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
Publication Details
- Journal
- Current Oncology
- Published
- 2026-02-02
- DOI
- https://doi.org/10.3390/curroncol33020089
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00